Veronique Erard1, Katherine A Guthrie2, Sachiko Seo3, Jeremy Smith3, MeeiLi Huang4, Jason Chien5, Mary E D Flowers6, Lawrence Corey7, Michael Boeckh8. 1. Division of Vaccine and Infectious Disease Clinic of Medicine, Hôpital Fribourgeois Fribourg, Switzerland and. 2. Division of Clinical Research Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Division of Vaccine and Infectious Disease. 4. Department of Laboratory Medicine. 5. Division of Clinical Research. 6. Division of Clinical Research Department of Medicine, University of Washington, Seattle. 7. Division of Vaccine and Infectious Disease Department of Laboratory Medicine Department of Medicine, University of Washington, Seattle. 8. Division of Vaccine and Infectious Disease Division of Clinical Research Department of Medicine, University of Washington, Seattle.
Abstract
BACKGROUND: Despite major advances in the prevention of cytomegalovirus (CMV) disease, the treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge. METHODS: We examined recipient, donor, transplant, viral, and treatment factors associated with overall and attributable mortality using Cox regression models. RESULTS: Four hundred twenty-one cases were identified between 1986 and 2011. Overall survival at 6 months was 30% (95% confidence interval [CI], 25%-34%). Outcome improved after the year 2000 (all-cause mortality: adjusted hazard ratio [aHR], 0.7 [95% CI, .5-1.0]; P = .06; attributable mortality: aHR, 0.6 [95% CI, .4-.9]; P = .01). Factors independently associated with an increased risk of all-cause and attributable mortality included female sex, elevated bilirubin, lymphopenia, and mechanical ventilation; grade 3/4 acute graft-vs-host disease was associated with all-cause mortality only. An analysis of patients who received transplants in the current preemptive therapy era (n = 233) showed only lymphopenia and mechanical ventilation as significant risk factors for overall and attributable mortality. Antiviral treatment with ganciclovir or foscarnet was associated with improved outcome compared with no antiviral treatment. However, the addition of intravenous pooled or CMV-specific immunoglobulin to antiviral treatment did not seem to improve overall or attributable mortality. CONCLUSIONS: Outcome of CMV pneumonia showed a modest improvement over the past 25 years. However, advances seem to be due to antiviral treatment and changes in transplant practices rather than immunoglobulin-based treatments. Novel treatment strategies for CMV pneumonia are needed.
BACKGROUND: Despite major advances in the prevention of cytomegalovirus (CMV) disease, the treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge. METHODS: We examined recipient, donor, transplant, viral, and treatment factors associated with overall and attributable mortality using Cox regression models. RESULTS: Four hundred twenty-one cases were identified between 1986 and 2011. Overall survival at 6 months was 30% (95% confidence interval [CI], 25%-34%). Outcome improved after the year 2000 (all-cause mortality: adjusted hazard ratio [aHR], 0.7 [95% CI, .5-1.0]; P = .06; attributable mortality: aHR, 0.6 [95% CI, .4-.9]; P = .01). Factors independently associated with an increased risk of all-cause and attributable mortality included female sex, elevated bilirubin, lymphopenia, and mechanical ventilation; grade 3/4 acute graft-vs-host disease was associated with all-cause mortality only. An analysis of patients who received transplants in the current preemptive therapy era (n = 233) showed only lymphopenia and mechanical ventilation as significant risk factors for overall and attributable mortality. Antiviral treatment with ganciclovir or foscarnet was associated with improved outcome compared with no antiviral treatment. However, the addition of intravenous pooled or CMV-specific immunoglobulin to antiviral treatment did not seem to improve overall or attributable mortality. CONCLUSIONS: Outcome of CMV pneumonia showed a modest improvement over the past 25 years. However, advances seem to be due to antiviral treatment and changes in transplant practices rather than immunoglobulin-based treatments. Novel treatment strategies for CMV pneumonia are needed.
Authors: Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas Journal: N Engl J Med Date: 1988-01-14 Impact factor: 91.245
Authors: A E Broers; R van Der Holt; J W van Esser; J W Gratama; S Henzen-Logmans; V Kuenen-Boumeester; B Löwenberg; J J Cornelissen Journal: Blood Date: 2000-04-01 Impact factor: 22.113
Authors: C M Machado; F L Dulley; L S Boas; J B Castelli; M C Macedo; R L Silva; R Pallota; R S Saboya; C S Pannuti Journal: Bone Marrow Transplant Date: 2000-08 Impact factor: 5.483
Authors: Takahiro Fukuda; Michael Boeckh; Katherine A Guthrie; Debra K Mattson; Stephanie Owens; Anna Wald; Brenda M Sandmaier; Lawrence Corey; Rainer F Storb; Kieren A Marr Journal: Biol Blood Marrow Transplant Date: 2004-07 Impact factor: 5.742
Authors: D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers Journal: Ann Intern Med Date: 1985-09 Impact factor: 25.391
Authors: Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Xiaofeng Zhou; David N O'Dwyer; Meng Xia; Holly K Miller; Paul R Chan; Kelsey Trulik; Mathew M Chadwick; Timothy C Hoffman; Camille Bulte; Kevin Sekerak; Carol A Wilke; Swapneel J Patel; Wayne M Yokoyama; Susan Murray; Gregory A Yanik; Bethany B Moore Journal: Am J Respir Crit Care Med Date: 2019-07-01 Impact factor: 21.405
Authors: Scott R Goldsmith; Michael Slade; John F DiPersio; Peter Westervelt; Steven J Lawrence; Geoffrey L Uy; Camille N Abboud; Ravi Vij; Mark A Schroeder; Todd A Fehniger; Erik R Dubberke; Kathryn Trinkaus; Rizwan Romee Journal: Haematologica Date: 2016-07-21 Impact factor: 9.941
Authors: Robin K Avery; Fernanda P Silveira; Kaitlin Benedict; Angela A Cleveland; Carol A Kauffman; Mindy G Schuster; Erik R Dubberke; Shahid Husain; David L Paterson; Tom Chiller; Peter Pappas Journal: Transpl Infect Dis Date: 2018-03-30 Impact factor: 2.228
Authors: Jason Chen; Justine Abella Ross; Bernard Tegtmeier; Dongyun Yang; James I Ito; John A Zaia; Jana K Dickter; Ryotaro Nakamura; Sally Mokhtari; Jane Kriengkauykiat; Monzr M Al Malki; Sanjeet S Dadwal Journal: Transpl Infect Dis Date: 2019-12-30 Impact factor: 2.228
Authors: Ashrit Multani; Libby S Allard; Tamna Wangjam; R Alejandro Sica; David J Epstein; Andrew R Rezvani; Dora Y Ho Journal: Blood Adv Date: 2019-11-26
Authors: Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta Journal: Blood Date: 2016-02-16 Impact factor: 22.113